Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

NCT04924062 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC